News

Releases included below may include references to both on-label and off-label usage of the HeartLight® Endoscopic Ablation System.
12
Jan
2021
12 Jan 2021

CardioFocus® Invited To Participate In 23rd Annual ICR Conference And Needham Virtual Growth Conference

MARLBOROUGH, Mass., Jan. 12, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that Chief Executive Officer & President Burke T. Barrett will present at the 23rd Annual ICR Conference, being held virtually January 11-14, 2021.

11
Jan
2021
11 Jan 2021

CardioFocus® Announces Expanded Distribution Partnership With MicroPort CRM To Include Spain And Portugal

MARLBOROUGH, Mass., Jan. 11, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that it has expanded its existing French distribution partnership agreement with MicroPort CRM in France to include both Spain and Portugal.

15
Dec
2020
15 Dec 2020

CardioFocus® Announces 10,000 Patients Treated Worldwide

MARLBOROUGH, Mass., June 16, 2020 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that more than 10,000 patients worldwide have been treated with the HeartLight® Endoscopic Ablation System.

16
Jun
2020
16 Jun 2020

CardioFocus® Announces Initial Commercial Procedures Following US FDA Approval of HeartLight® X3 System for the Treatment of Atrial Fibrillation

MARLBOROUGH, Mass., June 16, 2020 /PRNewswire/ — CardioFocus, Inc., today announced that the first U.S. patients have been treated commercially with the recently-approved HeartLight X3 Endoscopic Ablation System. The revolutionary cardiac ablation technology is designed to treat drug refractory, symptomatic paroxysmal atrial fibrillation (AFib), the most common heart rhythm disorder.

12
May
2020
12 May 2020

CardioFocus® Announces US FDA Approval of HeartLight® X3 System for the Treatment of Atrial Fibrillation

MARLBOROUGH, Mass., May 12, 2020 /PRNewswire/ — CardioFocus, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the next-generation HeartLight X3 Endoscopic Ablation System for the treatment of drug refractory symptomatic paroxysmal atrial fibrillation (PAF).

04
Feb
2020
04 Feb 2020

CardioFocus® Announces US FDA PMA Supplement Submission for the Breakthrough HeartLight® X3 Endoscopic Ablation System

MARLBOROUGH, Mass., February 4, 2020 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that the company has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for the HeartLight X3 Endoscopic Ablation System for the treatment of AFib. This supplement […]

22
Jan
2020
22 Jan 2020

CardioFocus® Names Burke T. Barrett as Chief Executive Officer

MARLBOROUGH, Mass., January 22, 2020 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that the Company’s Board of Directors has promoted Burke T. Barrett to the position of Chief Executive Officer (CEO), effective January 19, 2020. Mr. Barrett previously served as CardioFocus’ President and Chief […]

29
Oct
2019
29 Oct 2019

CardioFocus® Treats First Patients with HeartLight® Endoscopic Ablation System in France

MARLBOROUGH, Mass., October 29, 2019 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that the first patients in France have been treated at the Centre Hospitalier Régional Universitaire (CHRU) of Nancy with the HeartLight® Endoscopic Ablation System as part of an exclusive distribution partnership with MicroPort CRM […]

18
Jun
2019
18 Jun 2019

CardioFocus® Launches 100th HeartLight® Center Worldwide

MARLBOROUGH, Mass., June 18, 2019 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that the HeartLight® Endoscopic Ablation System is now offered at more than 100 hospitals worldwide.

28
May
2019
28 May 2019

CardioFocus® Secures $55 Million In Financing

MARLBOROUGH, Mass., May 28, 2019 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the completion of a $55 million round of financing.